Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Slow-releasing Tamoxifen citrate tablet

A technology of tamoxifen and citric acid, which is applied in the fields of peptide/protein components, pharmaceutical formulations, anti-tumor drugs, etc., and can solve the problems of the development and research status of tamoxifen citrate sustained-release preparations that have not been seen.

Inactive Publication Date: 2004-10-06
BEIJING CREATE FORTUNE TECH IND GRP CO LTD
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are no reports on the development and research status of tamoxifen citrate sustained-release preparations at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0191] Prescription (contains per 1000 tamoxifen citrate sustained-release tablets)

[0192] Tamoxifen Citrate 100g

[0193] Hypromellose (HPMC K4M) 90g

[0194] Polyvinylpyrrolidone (PVP K30) 100g

[0195] Lactose 85g

[0196] Micronized silica gel 100g

[0197] Magnesium stearate 10g

[0198] 80% ethanol aqueous solution

[0199] (1) Pass the prescribed amount of hydroxypropyl methylcellulose and polyvinylpyrrolidone through a 40-mesh sieve three times and mix them thoroughly.

[0200] (2) The tamoxifen citrate and the materials in (1) are first mixed in equal amounts by progressive addition, and then passed through a 40-mesh sieve three times to fully mix.

[0201] (3) Pass the lactose and the material in (2) through a 40-mesh sieve three times and mix them thoroughly.

[0202] (4) Pass the powdered silica gel and the materials in (3) through a 40-mesh sieve three times and mix them thoroughly.

[0203] (5) Add an appropriate amount of 80% ethanol solution to the above-mentione...

Embodiment 2

[0206] Prescription (contains per 1000 tamoxifen citrate sustained-release tablets)

[0207] Tamoxifen Citrate 1g

[0208] Hypromellose (HPMC K4M) 3g

[0209] Polyvinylpyrrolidone (PVP K30) 1g

[0210] Lactose 5g

[0211] Micronized silica gel 1g

[0212] Magnesium stearate 0.1g

[0213] 80% ethanol aqueous solution

[0214] (1) Pass the prescribed amount of hydroxypropyl methylcellulose and polyvinylpyrrolidone through a 40-mesh sieve three times and mix them thoroughly.

[0215] (2) The tamoxifen citrate and the materials in (1) are first mixed in equal amounts by progressive addition, and then passed through a 40-mesh sieve three times to fully mix.

[0216] (3) Pass the lactose and the material in (2) through a 40-mesh sieve three times and mix them thoroughly.

[0217] (4) Pass the powdered silica gel and the materials in (3) through a 40-mesh sieve three times and mix them thoroughly.

[0218] (5) Add an appropriate amount of 80% ethanol solution to the above-mentioned unifo...

Embodiment 3

[0221] Prescription (contains per 1000 tamoxifen citrate sustained-release tablets)

[0222] Tamoxifen Citrate 50g

[0223] Hypromellose (HPMC K4M) 45g

[0224] Polyvinylpyrrolidone (PVP K30) 50g

[0225] Lactose 42g

[0226] Micronized silica gel 50g

[0227] Magnesium stearate 5g

[0228] 80% ethanol aqueous solution

[0229] (1) Pass the prescribed amount of hydroxypropyl methylcellulose and polyvinylpyrrolidone through a 40-mesh sieve three times and mix them thoroughly.

[0230] (2) The tamoxifen citrate and the materials in (1) are first mixed in equal amounts by progressive addition, and then passed through a 40-mesh sieve three times to fully mix.

[0231] (3) Pass the lactose and the material in (2) through a 40-mesh sieve three times and mix them thoroughly.

[0232] (4) Pass the powdered silica gel and the materials in (3) through a 40-mesh sieve three times and mix them thoroughly.

[0233] (5) Add an appropriate amount of 80% ethanol solution to the above-mentioned un...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a slow-releasing preparation of Tamoxifen citrate as an anti-tumor medicine and its preparation method. Every tablet of Tamoxifen citrate contains 1 mg-100 mg, and the rest is slow-releasing material and auxiliary material.

Description

Technical field [0001] The invention relates to a sustained-release preparation of the anti-tumor drug tamoxifen citrate (Tamoxifen citrate) and a preparation method thereof. Background technique [0002] Tamoxifen citrate (Tamoxifen citrate), also known as tamoxifen, chemical name (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, The citrate of N-dimethylethylamine is a tristyrene non-steroidal anti-estrogen anti-tumor drug. By competitively binding with the estrogen receptor in the target cytoplasm, it blocks the effect of excessive estrogen on the breast tissue and reduces the excessive stimulation of estrogen on the ducts and interstitium of the breast. Therefore, it can be used for the treatment of breast cancer. In addition, the drug also has anti-oxidation, membrane regulation, multi-drug resistance (Multi-drug Resistance, MDR), cardioprotective function, anti-viral, anti-candida, and has an effect on insulin growth factor (can significantly reduce blood IGF- I (Level of Insuli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/22A61K31/195A61P35/00
Inventor 张强吴匡时张世勤
Owner BEIJING CREATE FORTUNE TECH IND GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com